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Implanon NXT is a single-rod progestin-only implant that contains 
68 mg of etonogestrel preloaded in a disposable applicator.[1] It is 
indicated for use by women to prevent pregnancy. Implanon NXT 
was first launched in Indonesia in 1998[2] and was approved by the US 
Food and Drug Administration in 2006.[3] Implants belong to a class 
of long-acting reversible contraceptives and along with intrauterine 
devices (IUDs) are referred to as the ‘most effective methods of 
reversible contraception’.[4] In 2012, the United Nations Commission 
on Life-Saving Commodities for Women and Children[4] endorsed 
contraceptive implants as one of its 13 life-saving commodities. 
According to the South African Demographic and Health Survey 
(SADHS) 2016, 58% of women (those currently married, and those 
sexually active and unmarried) use a modern contraceptive method, 
but 18% of women continue to have an unmet family planning need.[5] 
The SA National Contraceptive and Fertility Planning Policy aims to 
expand access to long-acting contraceptive methods.[6] The National 
Department of Health (NDoH) introduced Implanon NXT in 2014. 
In that year, insertions peaked in SA, with >175  000 insertions in 
the 2014/2015 reporting period, but this declined rapidly, with a 
50% decrease between 2014/2015 and 2015/2016,[7] and a 73% drop 
between 2014/2015 and 2016/2017.[8] The decline might be attributed 
to the pool of women interested in this method being saturated after 
the initial peak, with insertions continuing to stabilise at lower levels. 
Other explanations could include negative media reports[9-11] and 
community awareness of the side-effects. Another consideration is 
the release of a circular in October 2014 by the NDoH, recommending 
that women on enzyme-inducing drugs should not use the implant, 
but rather an alternative method, and those already on the implant 
should be given the option of removal.[12] Consequently, many 
antiretroviral (ARV) clinics across the country abruptly stopped 
providing Implanon NXT.[13]
Studies found that women may request early removal of the 
implant for a variety of reasons. Some of the initial international 
studies on Implanon NXT found that bleeding irregularities and other 
adverse events were common reasons for early removal.[14-16] Bleeding 
disturbances were the most frequent reason for discontinuation 
of implants in a large multicentre study in 7 countries.[17] Other 
adverse events leading to discontinuation included weight gain, acne, 
emotional lability and headaches.[14] A limited number of studies 
in SA have investigated discontinuation of the implant. A study 
conducted in the Eastern Cape found that side-effects such as heavy 
bleeding, severe headache and painful arm were the main reasons for 
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Background. The contraceptive implant, Implanon NXT, was introduced in South Africa (SA) in 2014 and, although it offers multiple 
advantages, users may request to have it removed early for several reasons. The number of insertions of Implanon NXT has declined in SA 
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Objectives. To gain an understanding of patterns of Implanon NXT use, reasons for requesting removal and duration of use at the time of 
requesting removal. 
Methods. This was a cross-sectional study conducted at an urban public-sector reproductive health clinic in the eThekwini District of 
KwaZulu-Natal, SA. A total of 120 women ≥18 years of age requesting removal of Implanon NXT completed an interviewer-administered 
questionnaire that probed experiences of use and reasons for removal. Data were collected electronically on Wits REDCap (Research 
Electronic Data Capture) and analysed using Stata 14 (StataCorp, USA). The study was conducted from 2017 to 2018. 
Results. A total of 120 women were interviewed. Their mean age was 28 (range 19 - 44) years and most women (n=103; 85.8%) had 
completed secondary school. The majority were black (n=115; 95.8%) and unmarried (n=102; 85%). Implants had been inserted primarily 
by nurses (n=110; 91.7%) at public-sector clinics (n=91; 75.8%). Three-quarters of the women (n=91; 75.8%) requested removal of Implanon NXT 
because it had reached the intended 3-year duration. Reasons for early removal were mainly due to side-effects, e.g. bleeding problems 
(n=19; 15.8%), weight gain (n=7; 5.8%), loss of libido (n=2; 1.7%), headaches (n=5; 4.2%), dizziness (n=4; 3.3%) and pain/numbness 
in the arm (n=2; 1.7%). Just more than half (57.1%) of the women who had received the implant for the intended 3-year duration had 
requested reinsertion of Implanon NXT. 
Conclusions. The main reason for requesting removal was that Implanon NXT had reached its intended 3-year duration, and more than 
half of the women requested reinsertion of the device following removal. Implanon NXT is a highly effective, safe, acceptable, long-acting 
contraceptive and important in the SA contraceptive method mix. 
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early Implanon NXT removal – the mean duration of use was 
11.2  months.[18] Another study conducted in 2 provinces in SA found 
that 90% of removals were due to side-effects and two-thirds related 
to changed bleeding patterns.[19] One study conducted at a hospital in 
KwaZulu-Natal (KZN) found that ~50% of Implanon NXT removals 
were due to abnormal uterine bleeding.[13] 
Users may also have the implant removed for reasons other than side-
effects. Studies indicated that reasons such as the desire to conceive, 
receiving other medical treatment (e.g. ARVs), misinformation and 
rumours, planning to go abroad and inadequate counselling might 
also result in early removal.[18,19] A local study conducted among 
nurses found that they lacked confidence in providing implant services 
effectively and generally held negative views towards the method, but 
the study was limited by its sample size.[20] 
Reasons for implant removal are not well reported in SA and 
there are limited data from KZN, which has the highest recorded 
uptake of Implanon NXT.[5] This study aimed to look at the reasons 
for requesting removal of Implanon NXT in an urban reproductive 
health clinic ~3 years after its introduction in SA, amid declining 
rates of insertions and concerns about early removals. 
Methods
A descriptive cross-sectional study among Implanon NXT users 
who requested removal was conducted at an urban public-sector 
reproductive health clinic in the eThekwini District of KZN, where 
~6 000 women attend per month. A range of services are provided 
at no cost and include HIV counselling and testing, initiation 
and management of patients on ARVs, cervical cancer screening, 
diagnosis and management of sexually transmitted infections, family 
planning services and assessment and management of gynaecology 
patients. The clinic also provides contraceptive training (including 
implant insertions and removals) to medical and nursing students, 
as well as doctors and nurses. Women attending this clinic include 
students in higher education, and urban and peri-urban women 
(employed and unemployed). The clinic is centrally located and 
provides services to a diverse population of women who live and 
work in the city centre, but also to many women from surrounding 
urban and peri-urban areas – up to 30 km away. 
A total of 120 women were interviewed from December 2017 to 
April 2018 using consecutive sampling. Interviews were conducted 
in English or isiZulu, depending on participant preference. DoH 
clinic staff were introduced to the study and were asked to refer 
all women requesting Implanon NXT removal to study staff, who 
provided them with an information sheet with regard to the study. 
To be eligible for the study, women had to be ≥18 years old, 
should have requested removal of the Implanon NXT device or have 
had the implant removed on the day of the interview, should have 
documented proof of the family planning card requesting removal 
or of having had the Implanon NXT removed, should have been 
willing to provide informed consent and must be either English or 
isiZulu speaking. Written informed consent was obtained. Women 
were reimbursed ZAR70 for their time. 
Data were collected by trained study staff and included demo-
graphics, reproductive history and previous contraceptive use. 
Women were asked where they had first heard about Implanon NXT, 
who inserted it and at which facility, bleeding pattern while on Impla -
non NXT, side-effects experienced and whether they would consider 
having the implant reinserted in the future. We also asked questions 
relating to reasons for requesting removal of the implant and the next 
method the woman intended to use after removal. Early removals 
were defined as those prior to 3 years from the date of insertion. Data 
were collected electronically on Wits REDCap (Research Electronic 
Data Capture), using tablets. Data were analysed using Stata 14 
(StataCorp, USA).[21]
Ethical approval
The study was approved by the Human Research Ethics Committee, 
University of the Witwatersrand, Johannesburg, SA (ref. no. 170109), 
and by the KZN Provincial DoH (ref. no. HRKM 158/17). A letter of 
support was obtained from the public-sector clinic where the study 
was conducted. 
Results
A total of 120 women requesting removal of Implanon NXT were 
interviewed from December 2017 to April 2018. Their mean age 
was 28 (range 19 - 44) years. Almost a third (n=38; 31.7%) of users 
were between the ages of 18 and 24 years. Most were black (n=115; 
95.8%) and had completed secondary school (n=103; 85.8%). Half 
of the women were employed and two-thirds (n=83; 69.2%) were 
unmarried and did not live with their current partner. 
Most women (n=97; 80.8%) reported ever being pregnant and a 
third (n=40; 33.3%) planned to have children in the future. About a 
fifth were nulliparous. When asked about previous contraceptive use, 
half (n=67; 55.8%) had used the 3-month injectable method, 27 (22.5%) 
used the 2-month injectable method, and 85 (70.8%) had used male 
condoms. None had used the IUD previously. Five (4.2%) women had 
previously used Implanon NXT. Table 1 provides study participant 
characteristics. 
Almost half of the women had heard about the implant from 
clinic staff (n=57; 47.5%) or a friend or relative (n=53; 44.2%). 
Implant insertions had been carried out primarily by nurses (n=110; 
91.2%) and at public-sector clinics (n=91; 75.8%). About a quarter of 
insertions (n=27; 22.5%) were carried out at government hospitals. 
Only 49 (40.8%) implants were inserted at the clinic where the study 
was conducted. Two-thirds (n=77; 64.2%) of the women chose to 
use Implanon NXT, as it was a long-acting method, and half (n=60; 
50%) because they did not want to return to the clinic frequently for 
follow-up. 
Women were asked regarding counselling or information provided 
prior to insertion. Most reported being counselled on how long the 
implant lasts (n=103; 86.6%) and when to return for removal (n=105; 
88.2%). Ninety-three (78.2%) women were counselled on possible 
side-effects, two-thirds (n=79; 66.4%) recalled being counselled on 
the advantages of the implant, and only 9 (7.6%) could not remember 
what counselling they had received before insertion of the implant. 
Three-quarters (n=91; 75.8%) of women had kept the implant for 
a duration of ≥3 years. The remaining quarter had requested removal 
of the implant before 3 years (Table 2).
The main reason for requesting Implanon NXT removal (n=91; 
75.8%) was because it had reached its intended 3-year duration. 
Women could select multiple responses as reasons for requesting 
removal of the implant. From the 29 early removals, 24 (82.8%) 
women mentioned side-effects as a reason. Bleeding was the most 
common reason for early removal of the implant (n=19; 15.8%), with 
14 women reporting prolonged or heavy bleeding and 10 reporting 
irregular bleeding. Other side-effects leading to early Implanon NXT 
removal were weight gain (n=7; 5.8%), loss of libido (n=2; 1.7%), 
headaches (n=5; 4.2%), dizziness (n=4; 3.3%) and pain/numbness in 
the arm (n=2; 1.7%). 
Five women had requested early implant removal for reasons other 
than side-effects – 2 of them had reported being pregnant or wanting 
to conceive. One woman had the implant removed at her partner’s 
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request (religious reasons), 1 implant was removed at the provider’s 
suggestion owing to concern regarding drug interaction between 
antiretroviral treatment (ART) and the implant, and the fifth removal 
was at the request of the participant owing to relocation and concern 
about finding a facility where it could be removed. 
Only 4 (3.3%) women requested removal of the implant (both early and 
at 3 years) because of pregnancy or wanting to conceive. Two cases of 
pregnancy were reported while the women were on Implanon NXT – 
1 woman had been on the implant beyond the intended 3-year duration 
(3 years and 10 months), and her timing of conception was calculated 
Table 1. Characteristics of study participants
Characteristics n (%) (n=120)
Age, years
18 - 24                     38 (31.7)
25 - 30 41 (34.2)
31 - 35 26 (21.7)
36 - 40 12 (10)
>40 3 (2.5)
Race
Black 115 (95.8)
White 1 (0.8)
Coloured 2 (1.7)
Indian 1 (0.8)
Other 1 (0.8)
Highest level of education
Secondary school (incomplete)          17 (14.2)
Secondary school (complete) 35 (29.2)
Tertiary/college/university (incomplete)             28 (23.3)
Tertiary/college/university (complete)                                                                                                  40 (33.3)
Employed
Yes 60 (50.0)
No 60 (50.0)
Relationship with partner
Married and living together                                          13 (10.8)
Married and not living together                                                5 (4.2)
Not married and living together                                                                                                                                        19 (15.8)                                                        
Not married and not living together                                                                                                                        83 (69.2)
Ever pregnant
Yes 97 (80.8)                                                                     
Pregnancies, n
0 23 (19.2)
1 - 2               74 (61.7)                                                                                    
≥ 3 23 (19.2)
Living children, n
0 2 (1.7)
1 - 2                                                                                       78 (65)
≥ 3 17 (14.2)
Plan on having more children
Yes 40 (33.3)
No 62 (51.2)
Maybe 18 (15)
Contraceptive method ever used 
Male condoms                                      85 (70.8)
Female condoms                                       3 (2.5)
3-month injection                   67 (55.8)
2-month injection                                                 27 (22.5)
Oral contraceptive                     23 (19.2)
Implanon NXT 5 (4.2)
Emergency contraception                       2 (1.7)
Natural methods, e.g. withdrawal                       0
Intrauterine device 0
None 7 (5.8)
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to be ~6 months after her implant had reached its 3-year duration. The 
other participant reported a positive home urine pregnancy test, but 
was awaiting confirmation of pregnancy by ultrasound examination, 
as the clinic urine pregnancy test was negative. On further follow-up, 
this participant was confirmed to be pregnant. Table 3 lists reasons for 
requesting removal of Implanon NXT. 
The 5 women who reported previous Implanon NXT use had it 
removed early (≤12 months) after the second insertion. Four of these 
women requested early removal owing to side-effects, and 3 of these 
had experienced no problems with the initial implant. Table 4 lists 
reasons for removal of Implanon NXT in women who had used it 
previously. 
Over half (n=52; 57.1%) of the 91 women who had been using the 
implant for 3 years chose to reinsert it after removal. Of the remaining 
39 women, 6 (6.6%) chose male condoms, 13 (14.3%) injectables, 
5 (5.5%) an IUD, 5 (5.5%) oral contraceptives, 2 (2.2%) tubal ligation, 
and 7 (7.7%) no method. Table 5 shows the contraceptive method 
chosen by women who had been on Implanon NXT for 3 years. Of 
the 7 women who chose to use no method, 3 wished to conceive, 1 was 
pregnant, 2 did not desire contraception (not sexually active) and 
1 wanted her menses to return before choosing her next contraceptive 
method. Hence, just over a third of women (n=31; 34.1%) elected to 
use a different contraceptive method after keeping Implanon NXT for 
its intended 3-year duration. 
More than half of the women (n=73; 60.8%) reported that they 
would be willing to insert Implanon NXT in the future. 
Discussion
This study provides important information and useful insights into 
patterns of Implanon NXT use and reasons for requesting removal 
among users in KZN. The study was conducted ~3 years after the 
introduction of Implanon NXT in SA and therefore provides an 
important indication about trends in usage, as all users requesting 
removal were interviewed and not only those requesting early 
removal. It is also a time when one would expect public awareness 
and use to have stabilised and provider skills to be optimised. 
We found high levels of satisfaction regarding the implant and 
three-quarters of the women remained on Implanon NXT for 3 years. 
They had requested removal, as the implant had reached its intended 
duration of use. Side-effects accounted for the majority of early 
removals, and the most common side-effect leading to early removal 
was bleeding. This has been found in several other studies;[14-17] 
bleeding changes are expected with Implanon NXT use. Similar 
findings were found in another SA study, where 90% of early 
Table 2. Duration of Implanon NXT use at the time of 
requesting removal 
Duration n (%) (n=120)
<6 months                                                   9 (7.5)
6 months - 1 year                                        4 (3.3)
>1 year, <2 years                                      6 (5)
≥2 years, <3 years 10 (8.3)
3 years                                                                                                 91 (75.8)
Table 3. Reasons for requesting removal of Implanon NXT 
Reason n (%) (n=120)
Reached intended 3-year duration                        91 (75.8)
Problems with bleeding                  19 (15.8)
Weight gain                                                               7 (5.8)
Headaches                   5 (4.2)
Dizziness 4 (3.3)
Loss of libido                                             2 (1.7)
Pain/numbness in the arm                                               2 (1.7)
Pregnancy*/want to conceive                                         4 (3.3)
Other 3 (2.5)
*Two cases of confirmed pregnancy were reported on Implanon NXT. One woman was 
on Implanon NXT beyond the intended 3-year duration. The other woman reported a 
positive urine pregnancy test done at home, but a urine pregnancy test done at the clinic 
was negative. She was waiting for an ultrasound examination, and was confirmed pregnant 
on follow-up. 
Table 4. Reasons for removal of Implanon NXT in women who had used it previously
Participant 
Duration of use of second 
Implanon NXT, months Reasons for requesting removal of second Implanon NXT
1 6 Weight gain, loss of libido                                                                                    
Loss of libido since the first implant insertion                                               
2 4 ‘Pregnancy symptoms’, but pregnancy tests had been negative                                                
Weight gain, dizziness and pain/numbness in the arm
No side-effects with the first implant  
3 12 Weight gain, problems with bleeding and prolonged nausea 
Nausea daily since insertion and patient suspected pregnancy
No side-effects with the first implant                    
4 6 Home pregnancy test was positive, but clinic urine pregnancy test was negative
Patient wanted implant removed because, if she was pregnant, it might affect the baby
On follow-up, confirmation of pregnancy
5 11 Problems with bleeding (prolonged/heavy bleeding)
No side-effects with the first implant
Table 5. Contraceptive method chosen after Implanon NXT 
removal in users who had been on the implant for 3 years
Contraceptive method                n (%) (n=91)
Implanon NXT                                                52 (57.1)
Male condoms                                             6 (6.6)
2-month injection                            6 (6.6)
3-month injection                         7 (7.7)
Intrauterine device 5 (5.5)
Oral contraceptives                       5 (5.5)
Tubal ligation 2 (2.2)
Unsure 1 (1.1)
No method 7 (7.7)
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removals were due to side-effects and two-thirds were related to 
changes in bleeding patterns.[19] This highlights the importance of 
counselling women about potential side-effects and how to manage 
them before providing the method. Few women reported weight 
gain, headaches and dizziness as reasons for early discontinuation of 
Implanon NXT. The side-effects reported in our study are consistent 
with the expected side-effects of Implanon NXT. We also noted that 
most women (n=93; 78.2%) recalled being counselled on side-effects 
prior to implant insertion, which might have contributed to a longer 
duration of Implanon NXT use. 
A very small number of women had requested Implanon NXT 
removal for reasons other than side-effects. One participant requested 
removal of the implant owing to the interaction between liver-inducing 
medication and the implant, resulting in reduced efficacy. This is 
in contrast to the study done in East London, SA, where 24 of 188 
(12.8%) implants were removed owing to women being on ARVs.[18] 
In the SA context, the interaction between efavirenz (EFV)-containing 
ARV regimens and Implanon NXT is important due to the high 
prevalence of HIV and the use of EFV in first-line ART regimens. The 
use of progestogen-only implants in women living with HIV and being 
administered ARVs is a World Health Organization Medical Eligibility 
for Contraception (MEC) category 2.[4]
Two women reported pregnancy as a reason for requesting removal 
of Implanon NXT. One of these women was on the implant beyond 
the indicated 3-year duration of use (3 years and 10 months) and her 
timing of conception was calculated as ~6 months after the implant 
had reached its duration of action. This is an interesting finding, 
as recent evidence suggests that etonogestrel-releasing implants are 
highly effective for an additional 2 years, i.e. up to 5 years.[22] The other 
woman was still awaiting confirmation of pregnancy by ultrasound at 
the time of her interview, but on follow-up she was confirmed to be 
pregnant. This low failure rate supports the high efficacy of Implanon 
NXT as a contraceptive method.[3] 
An unexpected finding was that all 5 women who had been on 
Implanon NXT for its full duration of use previously, had removed 
their second implant early and 4 of 5 had reported side-effects leading 
to removal. Since Implanon NXT was introduced in SA in 2014, there 
are limited data on repeat users. 
A third of Implanon NXT users were young women between 18 and 
24 years of age and just ˂20% were nulliparous, indicating that implant 
use is an acceptable contraceptive method in younger women. More 
than half of users requesting Implanon NXT removal had had their 
implants inserted at other health facilities, implying that our study 
findings might not be unique to the clinic where the study was con-
ducted. Contraceptive implants offer the benefit of a long duration of 
use and we found that the most common reasons for wanting to use 
Implanon NXT were the desire for a long-acting method and not want-
ing to return to the clinic frequently for follow-up.
Finally, we found that more than half of the women who had used 
Implanon NXT for its full duration chose to have it reinserted after 
removal, indicating satisfaction and acceptability of the method. We 
have shared these results with the DoH, and we recommend that 
similar data be collected in other settings to inform local practice and 
to understand the experiences of SA women with Implanon NXT. 
Study limitations
This was a cross-sectional study and women were not followed up 
prospectively. We only interviewed users at one clinic; therefore, 
the findings might not be generalisable to the larger population. 
There is potential selection bias, as the women who attended this 
clinic were from urban or peri-urban areas and the majority had at 
minimum completed secondary school. Staff at the clinic are involved 
in contraceptive teaching and training and might therefore be more 
experienced in managing side-effects and other problems, resulting 
in a longer duration of Implanon NXT use than at other facilities. 
Conclusions
Overall, our study findings indicate that three-quarters of women 
requested removal of Implanon NXT because it had reached its 
intended 3-year duration. 
Early removals were mainly due to side-effects. We also found that 
more than half of the women had Implanon NXT inserted again after 
having used it for 3 years. It is a highly effective, safe, acceptable, long-
acting contraceptive method and important in the SA contraceptive 
method mix. 
Despite declining rates of insertions and concerns about early 
implant removals, our results are reassuring and support the use of 
Implanon NXT as a highly effective, long-acting, safe contraceptive 
method. Most early removals were due to side-effects, highlighting 
the importance of counselling and effective management, especially 
of problematic bleeding. It is important that healthcare workers who 
provide Implanon NXT are adequately trained and experienced 
in managing side-effects. Our results should also be used to 
strengthen programming and reproductive health service delivery. 
Future research is needed on the experiences of women who have 
Implanon NXT reinserted after removal. Further studies using larger 
sample sizes and across multiple sites could provide valuable insight 
regarding experiences of women with Implanon NXT. 
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